RSI at 27, the CEO Steps In on a mutCALR Play
Damora is a clinical-stage biotech chasing therapies for blood disorders, and its lead antibody targets CALR mutations in essential thrombocythemia. The CEO wrote $252,875 at $20.23, buying while the stock sits near the bottom of its yearly range with RSI at 27 and the broad market still holding up, which is the washout setup with the best history. This is her first buy on the name, and every timeframe still reads Sell, so the tape is fighting her. Healthcare has been catching a defensive bid, which helps the timing, but a clinical-stage biotech lives and dies on trial data. Worth watching, not chasing.
The Filing
| Ticker | DMRA |
| Company | Damora Therapeutics, Inc. |
| Insider | Jennifer Jarrett, Director, President and CEO |
| Buy amount | $252,875 |
| Filing date | September 28, 2026 |
| Conviction | Interesting · 61/100 |
| Setup type | Contrarian Setup |
Ultimate members received this analysis in real time.